electroCore, Inc. Announces Extension of NHS England’s Innovation and Technology Payment (ITP) Program to Fund Continued Use of gammaCore in the U.K.

ITP program reimbursing for gammaCore extended to Sept. 30, 2020

BASKING RIDGE, N.J., April 08, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that England’s National Health Service (NHS) has exercised its option to extend the Innovation and Technology Payment (ITP) Program for the use of gammaCore in the treatment of cluster headache in adults. The extension will run through September 2020 and via this program, which started in April 2019, gammaCore will continue to be reimbursed for those patients in England who suffer from cluster headache and respond to our therapy.

“We are pleased to have NHS England maintain their ITP program to fund and support bringing our gammaCore therapy to patients suffering from cluster headache. gammaCore remains the only device approved by the National Institute for Health and Care Excellence (NICE) for use in patients with drug resistant cluster headaches,” said Iain Strickland, VP of European Operations, electroCore, Inc.

The ITP Program is designed to support the adoption of innovations and technologies in the NHS market through the removal of significant financial barriers for both commissioners and providers. The program provides funding to these MedTech products and promotes a broader set of activities with Academic Health Science Networks (AHSNs) in order to deliver improvements in the quality and efficacy of patient care.

About gammaCore
gammaCore (nVNS) is the first non-invasive, hand-held medical therapy FDA-cleared for the prevention of migraine headache, as an adjunctive therapy for the preventative treatment of cluster headache and as an acute treatment for pain associated with episodic cluster headache and migraine headache in adult patients. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers leading to a modulation of neurotransmitters and a reduction in pain.